Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117623 · ClinicalTrials.gov registry record · Phase 1
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT01117623: Completed Phase 1 study, sponsored by Bayer.
NCT01117623 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01117623, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
Continuous dosing of BAY73-4506 in patients with advanced cancer
Primary Outcome
The MTD was defined as the highest dose level, which could be given to 6 participants such that no more than 1 participant (less than 33%) experienced a dose-limiting toxicity (DLT).
Interventions
- DRUG Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg
- DRUG Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg
- DRUG Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
- DRUG Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg
- DRUG Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01117623 record still lists
NCT01117623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 5 interventions - of which Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg is the first listed.
NCT01117623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01117623 about?
NCT01117623 is a clinical study titled "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies". Continuous dosing of BAY73-4506 in patients with advanced cancer
What is the current status of trial NCT01117623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2007-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01117623?
The interventions under investigation include: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg (DRUG), Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg (DRUG), Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg (DRUG), Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg (DRUG), Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg (DRUG).
Who is sponsoring clinical trial NCT01117623?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01117623's enrollment target sits among peer trials
86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia